C5 Drug Candidate Efficacy & Toxicity
Aug 1, 2025·
·
1 min read
Meghan Forsythe
Evaluating C5 BCX candidates for efficacy and toxicity: Internship at BioCryst Pharmaceuticals.Abstract
During my Summer Internship at BioCryst Pharmaceuticals, I gained hands-on experience with industry drug discovery and assay development. My project focused on evaluating C5 BCX candidates for efficacy and toxicity using cutting-edge laboratory methods.
Type
Publication
BioCryst Pharmaceuticals Summer Internship Presentation
Project Overview
BioCryst Pharmaceuticals Summer Internship provided comprehensive training in drug development and laboratory skills. The main goal was to evaluate C5 BCX drug candidates for both efficacy and toxicity using industry-standard assays.
Techniques and Results
- Designed and executed AP ELISA, ZMAC30, and toxicity assays to evaluate small-molecule C5 inhibitors; calculated IC50 values using GraphPad Prism.
- Cultured and analyzed HepG2 cell models, assessing viability with CellTiter-Glo® to support efficacy and safety profiling.
- Performed intravenous rat dosing and plasma collection to inform pharmacokinetic and safety studies.
Internship Experience
This internship allowed for a deep understanding of the pharmaceutical workflow, from early-stage candidate evaluation to hands-on assay development and presentation to industry peers.
Media
Acknowledgements
Special thanks to the BioCryst mentors and lab team for providing training and support throughout this internship.
